Cargando…
Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer
BACKGROUND: (18)F-NaF positron emission tomography/computed tomography (fluoride PET/CT) is considered the most sensitive technique to detect bone metastasis in prostate cancer (PCa). (68)Ga-PSMA-11 (PSMA) PET/CT is increasingly used for staging of PCa. This study primarily aimed to compare the diag...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885936/ https://www.ncbi.nlm.nih.gov/pubmed/35229224 http://dx.doi.org/10.1186/s41824-022-00127-4 |
_version_ | 1784660544712605696 |
---|---|
author | Regula, Naresh Kostaras, Vasileios Johansson, Silvia Trampal, Carlos Lindström, Elin Lubberink, Mark Iyer, Victor Velikyan, Irina Sörensen, Jens |
author_facet | Regula, Naresh Kostaras, Vasileios Johansson, Silvia Trampal, Carlos Lindström, Elin Lubberink, Mark Iyer, Victor Velikyan, Irina Sörensen, Jens |
author_sort | Regula, Naresh |
collection | PubMed |
description | BACKGROUND: (18)F-NaF positron emission tomography/computed tomography (fluoride PET/CT) is considered the most sensitive technique to detect bone metastasis in prostate cancer (PCa). (68)Ga-PSMA-11 (PSMA) PET/CT is increasingly used for staging of PCa. This study primarily aimed to compare the diagnostic performance of fluoride PET/CT and gallium-based PSMA PET/CT in identifying bone metastasis followed by a comparison of PSMA PET/CT with contrast-enhanced CT (CE-CT) in identifying soft tissue lesions as a secondary objective. METHODS: Twenty-eight PCa patients with high suspicion of disseminated disease following curative treatment were prospectively evaluated. PET/CT examinations using fluoride and PSMA were performed. All suspicious bone lesions were counted, and the tracer uptake was measured as standardized uptake values (SUV) for both tracers. In patients with multiple findings, ten bone lesions with highest SUV(max) were selected from which identical lesions from both scans were considered for direct comparison of SUV(max). Soft tissue findings of local and lymph node lesions from CE-CT were compared with PSMA PET/CT. RESULTS: Both scans were negative for bone lesions in 7 patients (25%). Of 699 lesions consistent with skeletal metastasis in 21 patients on fluoride PET/CT, PSMA PET/CT identified 579 lesions (83%). In 69 identical bone lesions fluoride PET/CT showed significantly higher uptake (mean SUV(max): 73.1 ± 36.8) compared to PSMA PET/CT (34.5 ± 31.4; p < 0.001). Compared to CE-CT, PSMA PET/CT showed better diagnostic performance in locating local (96% vs 61%, p = 0.004) and lymph node (94% vs 46%, p < 0.001) metastasis. CONCLUSION: In this prospective comparative study, PSMA PET/CT detected the majority of bone lesions that were positive on fluoride PET/CT. Further, this study indicates better diagnostic performance of PSMA PET/CT to locate soft tissue lesions compared to CE-CT. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41824-022-00127-4. |
format | Online Article Text |
id | pubmed-8885936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-88859362022-03-08 Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer Regula, Naresh Kostaras, Vasileios Johansson, Silvia Trampal, Carlos Lindström, Elin Lubberink, Mark Iyer, Victor Velikyan, Irina Sörensen, Jens Eur J Hybrid Imaging Original Article BACKGROUND: (18)F-NaF positron emission tomography/computed tomography (fluoride PET/CT) is considered the most sensitive technique to detect bone metastasis in prostate cancer (PCa). (68)Ga-PSMA-11 (PSMA) PET/CT is increasingly used for staging of PCa. This study primarily aimed to compare the diagnostic performance of fluoride PET/CT and gallium-based PSMA PET/CT in identifying bone metastasis followed by a comparison of PSMA PET/CT with contrast-enhanced CT (CE-CT) in identifying soft tissue lesions as a secondary objective. METHODS: Twenty-eight PCa patients with high suspicion of disseminated disease following curative treatment were prospectively evaluated. PET/CT examinations using fluoride and PSMA were performed. All suspicious bone lesions were counted, and the tracer uptake was measured as standardized uptake values (SUV) for both tracers. In patients with multiple findings, ten bone lesions with highest SUV(max) were selected from which identical lesions from both scans were considered for direct comparison of SUV(max). Soft tissue findings of local and lymph node lesions from CE-CT were compared with PSMA PET/CT. RESULTS: Both scans were negative for bone lesions in 7 patients (25%). Of 699 lesions consistent with skeletal metastasis in 21 patients on fluoride PET/CT, PSMA PET/CT identified 579 lesions (83%). In 69 identical bone lesions fluoride PET/CT showed significantly higher uptake (mean SUV(max): 73.1 ± 36.8) compared to PSMA PET/CT (34.5 ± 31.4; p < 0.001). Compared to CE-CT, PSMA PET/CT showed better diagnostic performance in locating local (96% vs 61%, p = 0.004) and lymph node (94% vs 46%, p < 0.001) metastasis. CONCLUSION: In this prospective comparative study, PSMA PET/CT detected the majority of bone lesions that were positive on fluoride PET/CT. Further, this study indicates better diagnostic performance of PSMA PET/CT to locate soft tissue lesions compared to CE-CT. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41824-022-00127-4. Springer International Publishing 2022-03-01 /pmc/articles/PMC8885936/ /pubmed/35229224 http://dx.doi.org/10.1186/s41824-022-00127-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Regula, Naresh Kostaras, Vasileios Johansson, Silvia Trampal, Carlos Lindström, Elin Lubberink, Mark Iyer, Victor Velikyan, Irina Sörensen, Jens Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer |
title | Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer |
title_full | Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer |
title_fullStr | Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer |
title_full_unstemmed | Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer |
title_short | Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer |
title_sort | comparison of (68)ga-psma pet/ct with fluoride pet/ct for detection of bone metastatic disease in prostate cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885936/ https://www.ncbi.nlm.nih.gov/pubmed/35229224 http://dx.doi.org/10.1186/s41824-022-00127-4 |
work_keys_str_mv | AT regulanaresh comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer AT kostarasvasileios comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer AT johanssonsilvia comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer AT trampalcarlos comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer AT lindstromelin comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer AT lubberinkmark comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer AT iyervictor comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer AT velikyanirina comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer AT sorensenjens comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer |